These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31119890)

  • 1. Hydralazine and nitrates in the treatment of heart failure with reduced ejection fraction.
    Al-Mohammad A
    ESC Heart Fail; 2019 Aug; 6(4):878-883. PubMed ID: 31119890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of nitrates and hydralazine in heart failure: clinical evidence before the african american heart failure trial.
    Elkayam U; Bitar F
    Am J Cardiol; 2005 Oct; 96(7B):37i-43i. PubMed ID: 16226934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of isosorbide dinitrate and hydralazine in the management of heart failure in black patients, with a focus on a new fixed-dose combination.
    Cheng JW
    Clin Ther; 2006 May; 28(5):666-78. PubMed ID: 16861089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Hydralazine/Nitrate and Angiotensin Receptor Neprilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF).
    Giblin EM; Adams KF; Hill L; Fonarow GC; Williams FB; Sharma PP; Albert NM; Butler J; DeVore AD; Duffy CI; Hernandez AF; McCague K; Spertus JA; Thomas L; Patterson JH
    Am J Cardiol; 2019 Dec; 124(12):1900-1906. PubMed ID: 31679641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial.
    Ghali JK; Tam SW; Ferdinand KC; Lindenfeld J; Sabolinski ML; Taylor AL; Worcel M; Curry CL; Cohn JN;
    Am J Cardiovasc Drugs; 2007; 7(5):373-80. PubMed ID: 18041162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
    Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
    Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Quality of Care for US Veterans With Recent-Onset Heart Failure With Reduced Ejection Fraction.
    Sandhu AT; Kohsaka S; Turakhia MP; Lewis EF; Heidenreich PA
    JAMA Cardiol; 2022 Feb; 7(2):130-139. PubMed ID: 34757380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American Heart Failure Trial.
    Ferdinand KC; Elkayam U; Mancini D; Ofili E; Piña I; Anand I; Feldman AM; McNamara D; Leggett C
    Am J Cardiol; 2014 Jul; 114(1):151-9. PubMed ID: 24846808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate in African-American Patients With Heart Failure.
    Ziaeian B; Fonarow GC; Heidenreich PA
    JACC Heart Fail; 2017 Sep; 5(9):632-639. PubMed ID: 28711446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of hydralazine-isosorbide dinitrate combination in African American and other race/ethnic group patients with heart failure and reduced left ventricular ejection fraction.
    Golwala HB; Thadani U; Liang L; Stavrakis S; Butler J; Yancy CW; Bhatt DL; Hernandez AF; Fonarow GC
    J Am Heart Assoc; 2013 Aug; 2(4):e000214. PubMed ID: 23966379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial.
    Taylor AL; Ziesche S; Yancy CW; Carson P; Ferdinand K; Taylor M; Adams K; Olukotun AY; Ofili E; Tam SW; Sabolinski ML; Worcel M; Cohn JN;
    Circulation; 2007 Apr; 115(13):1747-53. PubMed ID: 17372175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vericiguat, organic nitrates, and heart failure in African Americans.
    Ilonze OJ; Guglin M
    Int J Cardiol; 2021 Sep; 338():136-137. PubMed ID: 34157357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mild systolic dysfunction in heart failure (left ventricular ejection fraction >35%): baseline characteristics, prognosis and response to therapy in the Vasodilator in Heart Failure Trials (V-HeFT).
    Carson P; Johnson G; Fletcher R; Cohn J
    J Am Coll Cardiol; 1996 Mar; 27(3):642-9. PubMed ID: 8606276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT.
    Cohn JN; Tam SW; Anand IS; Taylor AL; Sabolinski ML; Worcel M;
    J Card Fail; 2007 Jun; 13(5):331-9. PubMed ID: 17602978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics and Healthcare Utilization Among Veterans Treated for Heart Failure With Reduced Ejection Fraction Who Switched to Sacubitril/Valsartan.
    Mohanty AF; Levitan EB; Dodson JA; Vardeny O; King JB; LaFleur J; He T; Patterson OV; Alba PR; Russo PA; Choi ME; Bress AP
    Circ Heart Fail; 2019 Nov; 12(11):e005691. PubMed ID: 31718321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atrial fibrillation and mortality in African American patients with heart failure: results from the African American Heart Failure Trial (A-HeFT).
    Mitchell JE; Tam SW; Trivedi K; Taylor AL; O'Neal W; Cohn JN; Worcel M
    Am Heart J; 2011 Jul; 162(1):154-9. PubMed ID: 21742102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.
    Greene SJ; Choi S; Lippmann SJ; Mentz RJ; Greiner MA; Hardy NC; Hammill BG; Luo N; Samsky MD; Heidenreich PA; Laskey WK; Yancy CW; Peterson PN; Curtis LH; Hernandez AF; Fonarow GC; O'Brien EC
    J Am Heart Assoc; 2021 Aug; 10(16):e021459. PubMed ID: 34350772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilization of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: real-world data from the ARIADNE registry.
    Zeymer U; Clark AL; Barrios V; Damy T; Drożdż J; Fonseca C; Lund LH; Kalus S; Ferber PC; Hussain RI; Koch C; Maggioni AP
    Eur Heart J Qual Care Clin Outcomes; 2022 Jun; 8(4):469-477. PubMed ID: 33725113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology.
    Franciosa JA; Taylor AL; Cohn JN; Yancy CW; Ziesche S; Olukotun A; Ofili E; Ferdinand K; Loscalzo J; Worcel M;
    J Card Fail; 2002 Jun; 8(3):128-35. PubMed ID: 12140804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.